Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Donor Lymphocytes

Escalating doses of donor lymphocytes for incipient graft rejection following SCT for thalassemia

Bone Marrow Transplantation volume 45, pages 1047–1051 (2010)Cite this article

Abstract

Mixed chimerism (MC) and secondary graft failure are frequent events following SCT for thalassemia. There is limited information regarding the outcome of donor lymphocyte infusion (DLI) to prevent rejection, mainly from case reports describing only successful cases. We describe a series of seven children affected by β-thalassemia treated with escalating doses of DLI for level 2–3 MC (donor<90%) following myeloablative SCT from a matched family donor. The infusions were safe and no acute or chronic GVHD were documented; five patients experienced neutropenia and thrombocytopenia resolving spontaneously. DLI was successful in converting to full donor chimerism two patients stratified in the low-risk class (Pesaro class II). Conversely, for five high-risk patients, DLI was not effective in preventing secondary graft failure. This limited series suggests that escalating doses of DLI are safe in thalassemia patients post myeloablative therapy but efficacy may be jeopardized by rapidly growing anti-donor alloimmunity in high-risk patients. We suggest giving escalating doses of donor T cells to attempt a graft-versus-thalassemia as soon as level 2–3 MC is detected.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Lucarelli G, Gaziev J . Advances in the allogeneic transplantation for thalassemia. Blood Rev 2008; 22: 53–63.

    Article  PubMed  Google Scholar 

  2. Nesci S, Manna M, Andreani M, Fattorini P, Graziosi G, Lucarelli G . Mixed chimerism in thalassemic patients after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 143–146.

    CAS  PubMed  Google Scholar 

  3. Andreani M, Manna M, Lucarelli G, Tonucci P, Agostinelli F, Ripalti M et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 8: 3494–3499.

    Google Scholar 

  4. Andreani M, Testi M, Battarra M, Indigeno P, Guagnano A, Polchi P et al. Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. Blood Transfus 2008; 6: 143–149.

    PubMed  PubMed Central  Google Scholar 

  5. Gaziev J, Sodani P, Lucarelli G, Polchi P, Marktel S, Paciaroni K et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant 2008; 42: 397–404.

    Article  CAS  PubMed  Google Scholar 

  6. Elmaagacli AH, Beelen DW, Trenn G, Schmidt O, Nahler M, Schaefer UW . Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 771–777.

    Article  CAS  PubMed  Google Scholar 

  7. Zakrzewski JL . Successful management of impending late graft failure in a thalassemic bone marrow transplant recipient. Haematologica 2002; 87: ECR32.

    PubMed  Google Scholar 

  8. Tavil B, Kazik M, Kuskonmaz B, Cetin M, Uckan D . A prompt graft-versus-thalassemia effect upon withdrawal of cyclosporine A in a child who received allogenic peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 315–316.

    Article  CAS  PubMed  Google Scholar 

  9. Collins Jr RH, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  10. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  PubMed  Google Scholar 

  11. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  12. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67–71.

    CAS  PubMed  Google Scholar 

  13. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.

    CAS  PubMed  Google Scholar 

  14. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004; 33: 815–821.

    Article  CAS  PubMed  Google Scholar 

  15. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696–1705.

    Article  PubMed  Google Scholar 

  16. Bader P, Niemeyer C, Willasch A, Kreyenberg H, Strahm B, Kremens B et al. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy. Br J Haematol 2005; 128: 649–658.

    Article  PubMed  Google Scholar 

  17. Yoshimi A, Bader P, Matthes-Martin S, Starý J, Sedlacek P, Duffner U et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005; 19: 971–977.

    Article  CAS  PubMed  Google Scholar 

  18. Willasch A, Hoelle W, Kreyenberg H, Niethammer D, Handgretinger R, Lang P et al. Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. Haematologica 2006; 91: 788–794.

    PubMed  Google Scholar 

  19. Aker M, Kapelushnik J, Pugatsch T, Naparstek E, Ben-Neria S, Yehuda O et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bne marrow transplantation for beta-thalassemia major. J Pediatr Hematol Oncol 1998; 20: 145–148.

    Article  CAS  PubMed  Google Scholar 

  20. Baron F, Dresse MF, Beguln Y . Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic SCT for sickle cell disease. Transfusion 2000; 40: 1071–1073.

    Article  CAS  PubMed  Google Scholar 

  21. Ho HK, Chiang AK, Kwong YL, Chan GC, Lau YL, Ha SY . Pre-emptive treatment of early unstable mixed chimerism in a Chinese thalassaemia major patient by graded peripheral blood stem cell infusions. Haematologica 2003; 88: 5–7.

    Google Scholar 

  22. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329: 840–844.

    Article  CAS  PubMed  Google Scholar 

  23. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C . I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004; 33: 979–987.

    Article  CAS  PubMed  Google Scholar 

  24. Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004; 104: 1201–1203.

    Article  CAS  PubMed  Google Scholar 

  25. Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006; 12: 414–421.

    Article  PubMed  Google Scholar 

  26. Keil F, Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997; 89: 3113–3117.

    CAS  PubMed  Google Scholar 

  27. Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397–405.

    Article  CAS  PubMed  Google Scholar 

  28. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108–3114.

    Article  CAS  PubMed  Google Scholar 

  29. Fan Y, Xiao YB, Weng YG . Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. Transplant Proc 2009; 41: 1821–1824.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Immunohematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy

    I Frugnoli, B Cappelli, R Chiesa, E Biral, A Noè, C Evangelio, M Fossati, S Napolitano, M G Roncarolo & S Marktel

  2. San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milan, Italy

    B Cappelli, R Chiesa, E Biral, M G Roncarolo & S Marktel

  3. Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy

    F Ciceri

  4. Vita-Salute San Raffaele University Medical School, Milan, Italy

    M G Roncarolo

Authors
  1. I Frugnoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Cappelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Chiesa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Biral
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Noè
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Evangelio
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Fossati
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Napolitano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Ciceri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M G Roncarolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Marktel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Marktel.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frugnoli, I., Cappelli, B., Chiesa, R. et al. Escalating doses of donor lymphocytes for incipient graft rejection following SCT for thalassemia. Bone Marrow Transplant 45, 1047–1051 (2010). https://doi.org/10.1038/bmt.2009.298

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.298

Keywords

This article is cited by

Search

Advanced search

Quick links